-
公开(公告)号：US08193315B2
公开(公告)日：2012-06-05
申请号：US12842974
申请日：2010-07-23
IPC分类号： C07K14/705
CPC分类号： C07K14/70571 , C07H21/04
摘要： The invention provides isolated N-methyl-D-aspartate type 3B (NR3B) polypeptides, functional fragments and peptides, encoding nucleic acid molecules and polynucleotides, and specific antibodies. Also provided are excitatory glycine receptors, containing either NR3B or NR3A polypeptides. Further provided are methods for detecting excitatory glycine receptor ligands, agonists and antagonists. The invention also provides related diagnostic and therapeutic methods.
摘要翻译： 本发明提供分离的N-甲基-D-天冬氨酸3B型（NR3B）多肽，功能片段和肽，编码核酸分子和多核苷酸以及特异性抗体。 还提供了含有NR3B或NR3A多肽的兴奋性甘氨酸受体。 还提供了检测兴奋性甘氨酸受体配体，激动剂和拮抗剂的方法。 本发明还提供了相关的诊断和治疗方法。
-
32.发明授权公开(公告)号：US07732421B2
公开(公告)日：2010-06-08
申请号：US11750262
申请日：2007-05-17
申请人： John M. Yanni , Jon E. Chatterton , Diane Michelle Senchyna , Daniel A. Gamache , Steven T. Miller
发明人： John M. Yanni , Jon E. Chatterton , Diane Michelle Senchyna , Daniel A. Gamache , Steven T. Miller
CPC分类号： C12N15/1138 , A61K31/7088 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12N2310/346 , C12N2310/351 , C12N2320/30
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这样的TNFα靶标可用于治疗患有TNFα相关病症或具有发展TNFα相关病症如眼病干眼症，过敏性结膜炎或眼部炎症或诸如皮炎，鼻炎的患者的患者 ，或哮喘。
-
33.发明申请RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions 有权RNAi介导的脾脏酪氨酸激酶相关炎症病症的抑制公开(公告)号：US20090324507A1
公开(公告)日：2009-12-31
申请号：US12296621
申请日：2007-04-13
IPC分类号： A61K9/12 , A61K31/7105 , A61K48/00
CPC分类号： C12N15/1137 , A61K31/7105 , A61K31/713 , C07H21/02 , C12N15/113 , C12N2310/14 , C12N2310/531 , C12N2320/30
摘要： RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
摘要翻译： 提供RNA干扰用于抑制脾脏酪氨酸激酶（Syk）mRNA表达，特别是用于治疗患有Syk相关炎性病症的患者或具有发展Syk相关炎性病症如过敏性结膜炎，眼部炎症，皮炎， 鼻炎，哮喘，过敏或肥大细胞疾病。
-
公开(公告)号：US20090156470A1
公开(公告)日：2009-06-18
申请号：US12338252
申请日：2008-12-18
申请人： Jon E. Chatterton
发明人： Jon E. Chatterton
CPC分类号： A61K47/6455 , A61K47/645 , A61K47/65
摘要： The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
摘要翻译： 本发明提供了包含细胞穿透肽，聚精氨酸肽和干扰RNA分子的递送系统。 该系统可用于在体内或体外将干扰RNA分子递送至细胞中。 还提供了用于输送系统的治疗用途。
-
35.发明授权公开(公告)号：US08541389B2
公开(公告)日：2013-09-24
申请号：US13035147
申请日：2011-02-25
申请人： John M. Yanni , Jon E. Chatterton , Diane Michelle Senchyna , Daniel A. Gamache , Steven T. Miller
发明人： John M. Yanni , Jon E. Chatterton , Diane Michelle Senchyna , Daniel A. Gamache , Steven T. Miller
IPC分类号： C12N15/11
CPC分类号： C12N15/1138 , A61K31/7088 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12N2310/346 , C12N2310/351 , C12N2320/30
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFalpha）。 特别是沉默这种TNFα靶标，可用于治疗患有TNFalpha相关病症或有发生TNFalpha相关病症风险的患者，如眼病干眼症，过敏性结膜炎或眼部炎症，或诸如皮炎，鼻炎 ，或哮喘。
-
公开(公告)号：US08471000B2
公开(公告)日：2013-06-25
申请号：US13474405
申请日：2012-05-17
CPC分类号： C12N15/1136 , A61K9/0048 , A61K31/7105 , A61K31/713 , C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2320/30 , C12N2320/31
摘要： RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
-
37.发明授权公开(公告)号：US08222227B2
公开(公告)日：2012-07-17
申请号：US13173512
申请日：2011-06-30
IPC分类号： C12N15/11
CPC分类号： C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/141
摘要： RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
摘要翻译： 提供RNA干扰用于抑制组胺受体H1mRNA表达，特别是用于治疗患有HRH1相关病症或具有发生HRH1相关病症的风险的患者，例如过敏性结膜炎，眼部炎症，皮炎，鼻炎，哮喘或 过敏。
-
38.发明申请公开(公告)号：US20120178794A1
公开(公告)日：2012-07-12
申请号：US13429889
申请日：2012-03-26
申请人： Jon E. Chatterton , Abbot F. Clark
发明人： Jon E. Chatterton , Abbot F. Clark
IPC分类号： A61K31/713 , A61P27/06 , A61P27/02
CPC分类号： C12N15/1137 , A61K31/7084 , C12N2310/14
摘要： RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.
摘要翻译： 提供了用于抑制Rho激酶mRNA表达以治疗眼部疾病患者的RNA干扰，特别是用于治疗眼内压，眼高压和青光眼。 Rho激酶mRNA靶标包括ROCK1和ROCK2的mRNA。
-
公开(公告)号：US07973019B1
公开(公告)日：2011-07-05
申请号：US12244027
申请日：2008-10-02
申请人： Jon E. Chatterton , Abbot F. Clark
发明人： Jon E. Chatterton , Abbot F. Clark
CPC分类号： C12N15/113 , A61K9/0048 , A61K31/7088 , A61K31/713 , A61K47/64 , A61K47/644 , A61K47/6849 , C12N15/87 , C12N2310/14 , C12N2310/141 , C12N2310/3513 , C12N2320/32
摘要： The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
摘要翻译： 本发明提供可用作用于将干扰RNA分子在体外或体内递送至细胞的递送系统的干扰RNA分子 - 配体缀合物。 缀合物包含可结合转铁蛋白受体（TfR）的配体。 还提供了缀合物的治疗用途。
-
公开(公告)号：US20140031414A1
公开(公告)日：2014-01-30
申请号：US14010749
申请日：2013-08-27
申请人： Anja Smith , Angela Reynolds , Jon E. Chatterton , Xinyu Zhang
发明人： Anja Smith , Angela Reynolds , Jon E. Chatterton , Xinyu Zhang
IPC分类号： C12N15/113
CPC分类号： C12N15/1136 , A61K31/713 , C12N2310/14
摘要： Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.
摘要翻译： 血管内皮生长因子A（VEGFA）是刺激新血管生长的细胞产生的化学信号，VEGFA的过度表达可导致不良生理条件。 通过鉴定提高这些siRNA在体内的沉默能力的新siRNA和修饰，已经发明了治疗组合物和方法来解决与这种过度表达相关的问题。
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.035 秒)
